Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Arepanrix)
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is an FDA-licensed reference biologic from ID Biomedical Corporation of Quebec. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2013
Reference approved
Reference product
Arepanrix Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
ID Biomedical Corporation of Quebec
- Approved
- Nov 22, 2013
- Marketing
- Disc
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, in chronological order.
Reference approval
Approval date of the reference Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted product.
12 yr 8 mo ago
Frequently asked questions
Are there biosimilars approved for Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Arepanrix)?
No 351(k) biosimilars or interchangeable biosimilars referencing Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.